• The rapid rise of AI is already reshaping electricity consumption worldwide.
• Frontieras’ proprietary FASForm technology processes coal into multiple high-value outputs rather than using it solely for combustion.
• The company also focuses on infrastructure compatibility.

Artificial intelligence (“AI”) is transforming the way the world uses energy. From massive data centers to advanced manufacturing systems, the technologies powering the AI boom require enormous amounts of reliable electricity, putting growing pressure on existing energy infrastructure. Frontieras North America is positioning itself within that shift through its proprietary FASForm(TM) platform, which converts coal into fuels, hydrogen and industrial products, changing one of the world’s most abundant resources into a multi-output industrial energy system.

The rapid rise of AI is already reshaping electricity consumption worldwide. According to the International Energy Agency, global electricity demand from data centers is expected to more than double by 2030, driven largely by artificial intelligence applications and large-scale computing systems. The agency estimates that electricity demand from data centers could reach more than 945 terawatt-hours by the end of the decade, a level greater than the current annual electricity consumption of many industrialized nations.

That growth is placing increasing pressure on power grids and energy infrastructure. AI systems require massive computing capacity, and those systems consume large amounts of electricity around the clock. Training advanced AI models, operating hyperscale data centers and supporting cloud computing networks all depend on a reliable energy supply. Unlike some sectors where energy demand fluctuates throughout the day, large AI infrastructure systems often require stable baseload power operating continuously.

Major technology companies have already begun investing heavily in energy infrastructure to support future AI demand. According to Reuters, several large data center projects under development in the United States are expected to require power consumption levels comparable to those of small cities. Utilities and grid operators have also warned that rising electricity demand tied to artificial intelligence, electrification and industrial expansion is creating new strain on existing generation systems and transmission networks.

Frontieras North America is advancing a different approach to energy and industrial production that addresses these concerns. The company’s proprietary FASForm technology processes coal into multiple high-value outputs rather than using it solely for combustion. The system thermally fractionates coal into liquid fuels, hydrogen and purified industrial carbon products through a continuous-feed process that captures and repurposes byproducts.

The company positions coal not as a declining resource but as an underutilized one. Coal remains one of the most abundant energy resources in the world, with global proved recoverable coal reserves totaling approximately 1.16 trillion short tons. The Frontieras model is built around increasing the value extracted from that resource by converting it into multiple industrial and energy products simultaneously.

FASForm produces diesel, naphtha, jet fuel, hydrogen, FASCarbon(TM) (technical carbon) and ammonium sulfate fertilizer from a single feedstock stream, according to company materials. These products serve established global industries tied to transportation, manufacturing, aviation, refining, agriculture and industrial production; the markets connected to the company’s product portfolio exceed a combined estimated value of $2.1 trillion.

In addition, hydrogen production is becoming particularly important as industrial energy demand rises. Hydrogen is widely used in refining, industrial processing and chemicals manufacturing, and Frontieras generates hydrogen directly as part of its fractionation process. The company’s first planned commercial-scale facility in Mason County, West Virginia, is designed to generate more than 20 million standard cubic feet of hydrogen per day while processing approximately 7,500 tons of coal daily.

Frontieras also focuses on infrastructure compatibility. Rather than replacing existing industrial systems, the company’s FASGEN(TM) platform upgrades coal infrastructure by intercepting coal before combustion and routing it through the FASForm process to produce multiple energy and material streams. This approach allows existing coal infrastructure to serve broader industrial markets while leveraging established transportation and supply-chain networks.

In addition, the company owns a patent for its exclusive Witherspoon method, named after company cofounder and CTO Joseph Witherspoon. This process works with FASForm to produce large volumes of fertilizer and other usable industrial products from otherwise would-be waste material, such as sulfur and other compounds. These outputs are integrated directly into the economics of the system, alongside fuels, hydrogen and industrial carbon.

As AI continues driving global energy demand higher, industries and governments alike are searching for scalable systems capable of supporting long-term industrial growth. Frontieras North America is positioning its FASForm platform within that landscape. The company’s unique approach transforms coal into a diversified industrial resource tied to fuels, hydrogen and large-scale manufacturing markets. In an era increasingly defined by energy-intensive technologies, the company’s model focuses on extracting greater value from one of the world’s largest and most established energy resources.

For more information about Frontieras, visit the company’s website at www.Frontieras.com.

NOTE TO INVESTORS: The latest news and updates relating to Frontieras are available in the company’s newsroom at https://ibn.fm/Frontieras

• Oncotelic Therapeutics maintained the fair value of its 45% GMP Biotechnology JV stake at approximately $388 million in Q1 2026 despite broader biotech market volatility
• The valuation was supported by an independent ASC 820 Level 3 assessment using discounted cash flow analysis and market comparables
• These developments reinforce Oncotelic’s partnership-driven model, designed to advance a multi-billion-dollar oncology pipeline while limiting traditional biotech cash burn pressures

Oncotelic Therapeutics (OTCQB: OTLC) continues to distinguish itself within a biotechnology sector often characterized by aggressive capital raises and persistent cash burn. In its recently filed first-quarter 2026 financial results, the company maintained the fair value of its 45% ownership stake in GMP Biotechnology Limited at approximately $388 million, signaling relative stability during a period in which many emerging biotech valuations have faced significant downward pressure (ibn.fm/zeoOT).

“We believe the first quarter of 2026 continues to provide validation for the strategic value of our diversified biotechnology platform,” said Dr. Vuong Trieu, CEO of Oncotelic. “During the quarter, we continued advancing our oncology and AI-enabled development initiatives while maintaining the previously established fair value assessment of our GMP Bio joint venture interest as disclosed in our U.S. Securities and Exchange Commission (“SEC”) filing.”

The valuation was derived from an independent ASC 820 Level 3 assessment that incorporated discounted cash flow methodologies alongside market comparable analysis. Notably, the company reported that no valuation adjustment was necessary during the quarter despite broader volatility affecting small-cap biotechnology and healthcare equities.

Unlike many early-stage biotech companies that rely heavily on recurring equity dilution to fund operations, Oncotelic has pursued a more partnership-driven strategy. Its GMP Biotechnology joint venture structure allows the company to leverage shared development infrastructure, in-house GMP manufacturing capabilities, and collaborative financing mechanisms designed to reduce direct operating cash demands. As a result, this model has helped the company maintain a comparatively modest cash burn profile relative to many traditional clinical-stage biotech peers pursuing fully internal development programs.

Investor interest also continues to center on the company’s broader pipeline potential. Previous third-party analysis from Frost & Sullivan estimated the combined valuation potential of Oncotelic’s pipeline assets at more than $1.7 billion, highlighting the scale of opportunity across its oncology and rare disease programs (ibn.fm/wBSmO).

As demonstrated by investor interest in platform-driven biotechnology companies such as Northwest Biotherapeutics (OTC: NWBO), CytoDyn (OTC: DYDY), Sangamo Therapeutics (OTC: SGMO), and most recently Insilico Medicine (OTC: ISLMF)—which completed the largest biotechnology IPO in Hong Kong in 2025 and achieved a market capitalization exceeding US$2 billion following its public debut—investors continue to assign significant value to companies built around differentiated therapeutic and technology platforms rather than a single product opportunity.”

At the center of the company’s portfolio is OT-101 (Trabedersen), a first-in-class antisense RNA therapeutic targeting TGF-beta2, a pathway associated with tumor immune evasion and disease progression. The therapy has been evaluated across multiple cancer indications, including glioblastoma, pancreatic cancer, colorectal cancer, melanoma, and diffuse intrinsic pontine glioma (“DIPG”), a rare and aggressive pediatric brain cancer for which the company has received rare pediatric disease designation. OT-101 is currently advancing through later-stage development programs and combination studies involving checkpoint inhibitors and IL-2 immunotherapy approaches.

Beyond OT-101, Oncotelic maintains a diversified pipeline that includes CA4P, a vascular disrupting agent being explored for melanoma and solid tumors, OXi4503 for leukemia indications, and AL-101, an intranasal apomorphine candidate targeting Parkinson’s disease, erectile dysfunction, and female sexual dysfunction through the FDA’s 505(b)(2) regulatory pathway. The company has also expanded into nanoparticle delivery technologies and AI-enabled drug development initiatives through its proprietary PDAOAI platform, which is designed to support regulatory workflows, data analysis, and therapeutic discovery efforts.

The company’s strategy reflects growing industry interest in combining artificial intelligence with precision medicine and targeted therapeutics. Management believes this integrated approach could help accelerate development timelines while improving capital efficiency across multiple programs. Broader industry research continues to suggest that AI-driven drug discovery platforms may play an increasingly important role in reducing development costs and streamlining therapeutic identification in future biotechnology pipelines.

At the same time, the company’s regulatory filings provide important context for investors evaluating the story. Because the GMP Biotechnology stake is categorized as a Level 3 asset under ASC 820 accounting standards, the valuation relies heavily on internal assumptions and financial modeling rather than active public market pricing. In addition, the company continues to manage debt obligations and has included going-concern disclosures that are common among development-stage biotech firms. These factors remain important considerations when assessing the company’s overall risk profile and long-term investment potential.

For more information, visit the company’s website at www.Oncotelic.com.

NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at ibn.fm/OTLC

• MindWave Innovations is building institutional-grade digital asset treasury infrastructure designed to help corporations manage Bitcoin holdings through custody, reporting, and yield-generation capabilities
• The company’s broader ecosystem spans AdTech, InsurTech and ClimateTech, creating a multi-vertical blockchain-enabled platform
• Following its reverse merger with Apimeds Pharmaceuticals US, MindWave is now positioned as a publicly traded digital asset infrastructure company on the NYSE American

In corporate finance, treasury management has traditionally centered on capital preservation, liquidity, internal controls, and predictable yield. That framework is being tested as a growing number of companies leaning into Bitcoin not as a speculative trade, but as a strategic treasury asset. The first question was whether digital assets belonged on the balance sheet at all. The next question is more practical: how should institutions manage them?

MindWave Innovations Inc. (NYSE American: APUS) is positioning itself around that challenge through a blockchain-enabled financial infrastructure ecosystem designed for institutional digital asset management. The company is developing institutional-grade treasury infrastructure that combines custody, yield-generation capabilities, compliance-oriented reporting, and tokenized ecosystem functionality within a broader AI- and blockchain-powered platform architecture.

Rather than focusing solely on passive Bitcoin exposure, MindWave is building an interoperable ecosystem intended to support enterprise treasury operations, tokenized incentives, decentralized infrastructure participation, and cross-platform digital asset utility.

Moving Beyond Passive Bitcoin Ownership

Corporate Bitcoin adoption has evolved quickly. Early public-company strategies focused largely on acquisition and long-term holding, but treasury management extends well beyond ownership. Public companies must also consider custody, board oversight, reporting transparency, risk management, and capital efficiency.

That creates a different set of infrastructure requirements than those typically associated with early crypto markets. Much of the first generation of digital asset infrastructure was built around retail participation, speculative trading, or decentralized finance experimentation. Institutional treasury teams operate under a different set of expectations.

MindWave’s stated approach is aimed at that gap. Its platform is designed around segregated custody structures, insured protection mechanisms, and reporting frameworks intended to align digital asset management with traditional treasury disciplines.

Building a Treasury Infrastructure Stack

MindWave’s treasury strategy extends beyond custody alone.

The platform architecture is designed to function as an integrated treasury operating environment where custody, staking participation, yield optimization, reporting, and tokenized asset functionality operate within a connected ecosystem rather than through fragmented third-party solutions.

According to the company’s white paper, the ecosystem leverages validator-node participation, AI-driven analytics, blockchain interoperability frameworks, and tokenized service layers intended to create multiple forms of platform engagement and recurring utility.

A Multi-Vertical Ecosystem

Beyond treasury infrastructure, MindWave is building a broader digital ecosystem designed to connect multiple application areas.

Its AdTech vertical, Wave+, is structured to convert digital engagement into tokenized incentives through sustainability-linked participation models. The InsurTech framework combines blockchain-based mechanisms with traditional underwriting concepts intended to address digital asset protection. Its ClimateTech initiative, Aquae Impact, focuses on tokenized ecological and environmental asset verification.

Connecting these verticals is the company’s native $NILA token, which is intended to serve as the ecosystem’s economic layer for staking, interoperability, and service activation.

While the treasury business is likely the most immediately relevant to capital markets, the broader ecosystem reflects an effort to position the company at the intersection of digital assets, artificial intelligence, and blockchain-enabled enterprise infrastructure.

Public Market Positioning

MindWave’s public-market emergence followed its 2026 reverse merger with Apimeds Pharmaceuticals US, Inc. A recently announced settlement resolved outstanding disputes tied to that transaction, clearing the path for the completion of merger-related matters and the company’s previously disclosed up to $100 million PIPE financing.

The settlement also separated the legacy Apitox biopharmaceutical program into Lōkahi Therapeutics, allowing the company’s strategic focus to shift toward digital asset treasury infrastructure and technology development.

For digital asset infrastructure providers, public-company status may carry strategic relevance. Institutional counterparties often place value on transparency, and reporting discipline that align with their own internal controls.

The institutional Bitcoin treasury category remains early, but the direction is becoming clearer. As more companies consider digital assets as treasury holdings, the conversation may increasingly shift from ownership itself to the infrastructure required to manage those assets responsibly at scale. MindWave Innovations is building around that emerging opportunity.

For more information, visit the company’s website at www.MindWaveDAO.com.

NOTE TO INVESTORS: The latest news and updates relating to APUS are available in the company’s newsroom at https://ibn.fm/APUS

Disseminated on behalf of Nevada Organic Phosphate Inc. (CSE: NOP) (OTCQB: NOPFF) and may include paid advertising.

• The latest drilling at hole MM26-7 intersected approximately 39 metres of the targeted Meade Peak phosphatic interval, pending assay confirmation.
• The company is advancing a broader exploration program focused on the Upper Phosphatic Zone within the Meade Peak Member.
• Nevada Organic Phosphate is targeting the expanding North American market for direct application organic phosphate fertilizer.
• Domestic phosphate supply is becoming critical amid global fertilizer supply-chain uncertainty and geopolitical concentration risk.
• The Murdock Mountain Property benefits from access to highway, rail, and trucking infrastructure, serving national agricultural markets.

Nevada Organic Phosphate (CSE: NOP) (OTCQB: NOPFF), a B.C.-based leader in organic sedimentary phosphate exploration, recently reported encouraging preliminary observations from its ongoing 2026 drilling campaign at the Murdock Mountain Property in Elko County, Nevada. The company said drill hole MM26-7 intersected an apparent 39 metres of the targeted Meade Peak stratigraphic interval. The drill hole was completed to a depth of 152 metres and positioned roughly 100 metres north and upslope from drill hole MM25-1 completed during the prior exploration season (https://ibn.fm/S9rmS).

According to the company, last year’s MM25-1 hole intersected approximately 38 metres of the same Meade Peak interval.

Management noted that the current exploration focus remains the Upper Phosphatic Zone, a 3.4 to 7.6 metre interval located within the broader Meade Peak Member. That geological framework was originally identified through earlier trench observations and historical academic work.

Laboratory assays will be required to confirm phosphate grades, thickness variations and the true dimensions of the mineralized intervals encountered during the current drilling program.

Nevada Organic Phosphate also confirmed that drill hole MM26-8 has now been completed approximately 100 metres north of last year’s MM25-3 hole. Additional geological observations and collar data are expected once logging work is finalized.

The latest drilling update arrives as phosphate markets continue attracting renewed strategic attention. Phosphorus remains an essential agricultural nutrient, with approximately 90% of global phosphorus consumption tied to fertilizer production. While Morocco controls the world’s largest phosphate reserves and China remains the dominant phosphate fertilizer producer and exporter, Western agricultural markets continue seeking greater supply diversification amid geopolitical and logistical uncertainty.

Those concerns have intensified following recent disruptions to global fertilizer trade routes linked to instability around the Strait of Hormuz, a corridor through which a substantial portion of the world’s fertilizer shipments normally pass.

Nevada Organic Phosphate is attempting to position the Murdock Mountain Property within that broader shift toward domestic and regionally secure fertilizer supply. Unlike conventional phosphate operations that typically involve extensive downstream chemical processing, the company is focused on organic sedimentary phosphate suitable for direct application agriculture. Management says the project is designed around raw rock phosphate intended for grinding, bagging and direct agricultural use rather than large-scale chemical conversion. 

That distinction places the company within the expanding organic and regenerative agriculture sector. The company does not have to compete with the conventional chemical agricultural input industry.

American farming practices have increasingly shifted toward reactive phosphate products and soil-focused nutrient management systems intended to work alongside natural soil biology. Nevada Organic Phosphate argues its material may align with those trends because it can be applied directly to agricultural land without conventional chemical processing.

The company estimates the Murdock Project currently hosts an Exploration Target Mineral Inventory, or ETMI, ranging between 10 million and 46 million tonnes grading between 3% and 15% P2O5. The estimate is based on an average thickness of 3.5 metres and a specific gravity of 2.61.

In addition to the main Murdock Mountain target zone, the company has identified three additional target areas that could extend the overall phosphate-bearing strike length to more than 30 kilometres.

Importantly, Nevada Organic Phosphate emphasises that further drilling, geological interpretation and assay work will be required before the scale and continuity of mineralization can be fully assessed.

Infrastructure access may also represent an important operational advantage. The Murdock Mountain Property is situated near major transportation corridors, including highway access connecting to Montello and Elko, Nevada, as well as nearby rail infrastructure capable of serving national agricultural markets.

Nevada Organic Phosphate added that surveying work from the prior drilling campaign has now been completed by a licensed surveyor, with updated mapping expected in a future release. Additional 2026 drill collar surveys will also be completed as the exploration program advances. The company added that future technical disclosures, including assay results and detailed geological interpretations, will be reviewed by qualified independent geological professionals under applicable Canadian disclosure standards.

For more information, visit the company’s website at www.NevadaPhosphate.com.

NOTE TO INVESTORS: The latest news and updates relating to NOP are available in the company’s newsroom at https://ibn.fm/NOP

Blockchain Futurist Conference is returning to Florida. Following the success of its first-ever U.S. edition, the conference has officially confirmed its second annual Florida show for Nov. 17–18, 2026, bringing back the immersive, networking and business development-focused experience that has made the Toronto flagship one of the most recognized Web3 events in North America.

The Florida edition will once again be hosted at a signature indoor-outdoor venue, DAER Night & Day Club and DAER Rooftop inside the Seminole Hard Rock Hotel & Casino Hollywood, FL, staying true to Futurist’s philosophy of creating environments built for connection and deal-making rather than traditional convention center experiences. The 2025 U.S. debut confirmed strong demand for the Futurist experience in the American market, and the 2026 return will build on that momentum with expanded programming and a speaker lineup reflecting the continued growth of the industry.

Futurist Florida is now onboarding speakers and sponsors for the upcoming Fort Lauderdale event. Bringing together thousands of attendees from across the crypto, AI, and emerging tech sectors, the conference is currently seeking thought leaders to speak on topics including RWAs, stablecoins, regulation, institutional adoption, AI and Web3, tokenization, privacy, quantum security, infrastructure, and the future of digital finance. Companies looking to connect with founders, investors, developers, and decision-makers are also invited to explore sponsorship and exhibition opportunities.

As with the Toronto edition, Futurist Florida will feature multiple stages of programming, an expo floor, and the signature VIP cabana experience — private branded outdoor spaces designed for high-value networking and meetings with investors, executives, and industry leaders.

Early-bird ticket pricing is currently available. Tickets can be purchased at futuristconference.com/florida/ticket.

ETHWomen will also return alongside the Florida show, created to encourage more women to join and thrive in the Web3 industry.

Florida Tickets: futuristconference.com/florida/ticket

Sponsorships: futuristconference.com/sponsorship-form

Speaker Applications: futuristconference.com/speaker-form

For media passes or media inquiries, please contact james@futuristconference.com

• American Fusion(TM) management participated in strategic meetings and forums in Washington, D.C., focused on energy security, resilient infrastructure, and military power requirements.
• The company recently completed the structural frame for a 5-megawatt Texatron(TM) pre-production unit, an important step toward integrated system assembly and testing.
• American Fusion(TM) describes Texatron(TM) as a “Fusion Engine(TM)” platform, reflecting a commercial infrastructure approach rather than a laboratory-focused research model.
• The company is advancing multiple corporate initiatives, including anticipated Form 10 effectiveness, Rule 15c2-11 quotation eligibility efforts and a Frankfurt quotation application.
• Management says its long-term strategy centers on modular fusion systems designed for scalable deployment across industrial, commercial and grid-constrained applications.

American Fusion(TM) (OTC: AMFN), a developer of next-generation fusion energy technologies, is continuing to expand its presence within U.S. energy and defense discussions as the company advances development of its Texatron(TM) Fusion Engine(TM) platform. According to a recent company update, management participated in a series of strategic meetings and industry forums in Washington, D.C., where resilient energy infrastructure and long-term power security were recurring themes (https://ibn.fm/OdjZ8).

The meetings included engagements associated with the United States Energy Association and the Association of Defense Communities, organizations that frequently convene policymakers, infrastructure operators and defense-related stakeholders around issues tied to national energy resilience. During those discussions, American Fusion(TM) introduced aspects of its Texatron(TM) platform and its broader approach to compact fusion-based energy systems.

Management indicated that conversations centered on the long-term role advanced energy technologies could play in supporting defense installations, mission-critical infrastructure and distributed power systems. Executive Chairman Brent Nelson said one of the themes emerging from the discussions was the perception that the company’s technology is being viewed less as a conventional fusion research initiative and more as a practical energy platform aimed at infrastructure deployment.

“One of the recurring themes in Washington was that our technology is increasingly viewed less as a conventional fusion ‘science project’ and more as a practical energy platform. That distinction matters,” Nelson said. “Texatron(TM) is being developed as a Fusion Engine(TM) architecture designed around practical deployment, resilient power applications, and real-world infrastructure needs.”

That distinction is important for investors following the fusion sector. Much of the industry remains heavily focused on experimental validation and long-term scientific milestones. American Fusion(TM), by contrast, is attempting to position Texatron(TM) as a modular energy architecture designed around eventual commercial deployment and scalable infrastructure use cases.

The company recently announced completion of the structural frame for its 5-megawatt Texatron(TM) pre-production unit, which management describes as a key milestone ahead of integrated system assembly and controlled testing activities in Texas. The company is also continuing work related to diagnostics procurement, engineering integration and regulatory coordination.

While the company has reported successful plasma formation work using its proprietary pulsed torsatron design, the technology remains in development, but still focused on moving beyond scientific experimentation and toward engineering-driven commercialization strategies. American Fusion(TM) appears to be emphasizing that transition point in both its messaging and development roadmap. According to management, the company is currently pursuing multiple Texatron(TM) configurations, including a 5-megawatt demonstration-oriented system and a larger 100-megawatt design intended to support future commercial deployment concepts.

The modular structure of the company’s strategy is also notable. Management has described the architecture as scalable through standardized reactor units, allowing generation capacity to expand incrementally over time. In practical terms, multiple 100-megawatt systems could theoretically be combined into utility-scale generation infrastructure if the technology ultimately proves commercially viable.

The broader backdrop for these discussions is a growing focus on domestic energy resilience and infrastructure modernization. Rising electricity demand from data centers, industrial electrification and artificial intelligence computing workloads has renewed investor interest in next-generation baseload power technologies. Defense agencies and infrastructure planners have also increasingly discussed the strategic importance of resilient, distributed energy systems capable of operating independently from centralized grids.

American Fusion(TM) cautioned that participation in industry forums and stakeholder discussions does not constitute government endorsement or procurement activity. However, management stated that continued engagement with defense and energy policy communities remains an important part of positioning the Texatron(TM) platform within future infrastructure discussions.

Alongside technical development, the company is also advancing several capital markets initiatives. Management said it has submitted supporting documentation tied to an anticipated Rule 15c2-11 quotation application, which, if approved, could improve quotation visibility for the company’s shares.

For more information, visit the company’s website at www.AmericanFusionEnergy.com.

NOTE TO INVESTORS: The latest news and updates relating to AMFN are available in the company’s newsroom at https://ibn.fm/AMFN

• Safe Pro Group Has Been Invited to a U.S. Army Force-on-Force (“FoF”) Combat Exercise designed to train and equip soldiers with its patented battlefield threat detection system.
• In the exercise, Safe Pro will showcase the system’s capabilities for rapidly identifying explosive threats combined with enhanced battlefield mapping.
• This invite follows Safe Pro’s recent participation in a U.S. Army active minefield exercise where the drone imagery analysis platform helped battlefield decision-making and operational planning in a live threat environment.

Safe Pro Group (NASDAQ: SPAI), a mission-driven tech company that develops security and defense solutions, recently revealed that it has been invited to participate in an upcoming U.S. Army FoF combat training exercise scheduled for the second quarter of 2026 (https://ibn.fm/JDs3f). FoF exercises are one of the Army’s most realistic combat training exercises, as they simulate live battlefield conditions between military units.

During these exercises, Safe Pro has been tasked with training and equipping soldiers with its NODE-X, AI edge imagery processing and mapping solution powered by its patented Safe Pro Object Threat Detection (“SPOTD”) technology. At the exercise, Safe Pro will highlight the system’s ability to use AI to rapidly identify explosive threats and produce enhanced battlefield maps.

This FoF opportunity comes after Safe Pro recently, and successfully, participated in a U.S. Army active minefield exercise where Safe Pro’s drone imagery analysis platform helped operational planning and battlefield decision-making in a live threat environment. During the exercise, Safe Pro’s NODE-X provided rapid battlefield intelligence and outcomes, helping commanders make important decisions that impacted mission success.

NODE-X is the next generation of Safe Pro’s AI-powered toolset that’s designed to offer battlefield intelligence at the tactical edge, by quickly analyzing drone imagery for both mapping and threat detection, right in the field without the need for cloud or internet connectivity.

The miniaturized NODE-X system is built for military operations and combines rapid threat detection, 3D terrain mapping, automated route planning, orthomosaic generation, and edge-based drone intelligence processing all in one compact platform.

The system is also backpack-sized, rugged, can integrate into various U.S. Army vehicles, and is even compatible with U.S. Army-approved Short-Range Reconnaissance (“SRR”) drones to deliver battlefield intelligence to soldiers and their commanders.

NODE-X, which is powered by the SPOTD technology, uses AI and machine learning algorithms which are trained on one of the largest real-world drone-based imagery datasets focused on detecting landmines and other unexploded ordnance (“UXO”).

In fact, the platform is capable of identifying more than 150 explosive threats and related objects. Safe Pro’s AI dataset also includes more than 2.75 million drone images and has over 50,000 confirmed detections of small threats.

About Safe Pro Group Inc. (NASDAQ: SPAI)

Safe Pro Group is a mission-driven tech company that delivers AI-powered defense and security solutions, such as drone-based services and ballistic protective gear, to customers in a wide variety of industries. At the core of Safe Pro’s mission is computer vision software technology that rapidly detects and identifies small explosive threats in drone images and videos, to help enable safer field operations in conflict and post-conflict zones.

For more information, visit Safe Pro Group’s website at www.SafeProGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to SPAI are available in the company’s newsroom at https://ibn.fm/SPAI

Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising.

• Quantum BioPharma is advancing a clinical-stage multiple sclerosis program targeting demyelination, a differentiated approach compared to many existing therapies focused primarily on immune modulation.
• The company maintains royalty participation and equity ownership exposure to unbuzzd(TM) while preserving pharmaceutical and medical-use rights to related formulations.
• Lucid-MS has completed Phase 1 safety studies and advanced into the IND submission stage ahead of a planned Phase 2 clinical trial in multiple sclerosis.
• Quantum BioPharma’s portfolio spans both therapeutic drug development and consumer-focused wellness products, creating multiple potential operational and commercialization pathways.
• The company has reported sufficient working capital to sustain basic operations beyond January 2028 while continuing development across its pipeline and strategic initiatives.

Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is a biopharmaceutical company focused on developing therapies and biotech solutions targeting neurodegenerative, metabolic and alcohol misuse disorders. The company is advancing a diversified platform spanning clinical-stage therapeutics, consumer-focused wellness products and strategic investments designed to address areas of significant unmet need.

The company’s strategy combines pharmaceutical research and development with commercialization partnerships and licensing structures intended to support multiple potential revenue streams and long-term growth initiatives. Quantum BioPharma is advancing programs across multiple stages of development while leveraging scientific research, intellectual property and commercial relationships as part of its broader business strategy.

The company is headquartered in Toronto, Ontario.

Portfolio

Lucid-MS

Lucid-MS (Lucid-21-302) is a patented new chemical entity being developed as a potential treatment for multiple sclerosis and other demyelinating diseases. The compound has demonstrated in preclinical models the ability to prevent and reverse myelin degradation while preserving neuronal health. According to the company, Lucid-MS is designed as a non-immunomodulatory, neuroprotective therapy targeting demyelination, a key driver of disease progression in multiple sclerosis.

Quantum BioPharma completed Phase 1 Single Ascending Dose (“SAD”) and Multiple Ascending Dose (“MAD”) studies evaluating the safety and tolerability of Lucid-MS in healthy volunteers. The company submitted an Investigational New Drug (“IND”) application to the U.S. Food and Drug Administration in March 2026 to support a planned Phase 2 clinical trial in multiple sclerosis patients. The focus of the study is intended to be in patients suffering from PPMS (primary progressive) and SPMS (secondary progressive) types of the disease. Quantum BioPharma has also entered into a binding letter of intent with global clinical research organization Allucent to support the planned Phase 2 study.

Lucid-MS has been studied through more than a decade of research and development and has shown efficacy in several preclinical animal models. Quantum BioPharma maintains exclusive worldwide rights to the compound through its wholly owned subsidiary, Lucid Psycheceuticals Inc.

unbuzzd(TM) and REKVRY(TM)

Quantum BioPharma developed unbuzzd(TM), a dietary supplement beverage formulation designed to accelerate alcohol metabolism, reduce blood alcohol concentration and improve mental alertness following alcohol consumption. The company spun out the over-the-counter consumer version of the product to Unbuzzd Wellness Inc., formerly Celly Nutrition Corp., while retaining an ownership stake and royalty participation. Under the agreement, Quantum BioPharma retains a 7% royalty on sales of unbuzzd(TM) until aggregate payments reach $250 million, after which the royalty decreases to 3% in perpetuity. The company also retains 100% of the rights to develop similar products or alternative formulations for pharmaceutical and medical uses.

In March 2026, results from a double-blind, randomized, placebo-controlled crossover clinical trial investigating unbuzzd(TM) were published in a peer-reviewed scientific journal. According to the company, the study demonstrated statistically significant improvements in alcohol metabolism, reductions in blood alcohol concentration, improved alertness and reduced hangover symptoms compared to placebo.

Quantum BioPharma is also developing REKVRY(TM), a formulation intended for alcohol misuse treatment in hospital and emergency settings, which the company believes may help address healthcare burden associated with alcohol intoxication and misuse.

Market Opportunity

Quantum BioPharma is targeting large global markets across multiple sclerosis treatment, alcohol recovery products and functional wellness beverages. According to company materials, approximately 2.8 million people worldwide are living with multiple sclerosis, including nearly one million people in the United States alone. The company has cited projections indicating the global multiple sclerosis market could grow from approximately $28.2 billion in 2022 to approximately $41 billion by 2033.

The company is also targeting the growing hangover recovery and alcohol wellness market through unbuzzd(TM). According to Quantum BioPharma’s materials, the global hangover cure products market was valued at approximately $2.05 billion in 2022 and is projected to reach approximately $6.2 billion by 2030, representing a compound annual growth rate of 14.8%. Quantum BioPharma has additionally cited estimates that excessive alcohol consumption costs the United States approximately $249 billion annually through healthcare costs, lost productivity, criminal justice impacts, vehicle crashes and property damage. The company has also referenced projections estimating the broader functional beverage market could reach approximately $198 billion in 2026.

Leadership Team

Zeeshan Saeed, Founder, CEO, President & Executive Co-Chair, founded Quantum BioPharma and played a key role in securing the company’s initial seed capital and transition into a publicly traded company. Prior to founding Quantum BioPharma, he served as President of ZZ Telecommunications Inc., a long-distance telecommunications carrier, and previously founded Platinum Telecommunications Inc. Mr. Saeed has experience in international capital markets, including assisting startups with raising capital and securing exchange listings, and holds a Bachelor of Science in Mechanical Engineering.

Anthony Durkacz, Co-Founder & Executive Co-Chair and previously served as President of Capital Ideas Investor Relations, was the CFO and a director of Snipp Interactive, as well as was COO and CFO of MKU Canada and Astris Energi.

Donal Carroll, CPA, CFO & COO, has more than 20 years of corporate finance leadership and public company experience. Prior to joining Quantum BioPharma, he served as Country CFO with Videojet Technologies, a Danaher company, Accounting Supervisor with Alberto Culver, now part of Unilever, and Corporate Controller with Cardinal Meats.

Jason Sawyer, Head of Finance and M&A, is a veteran financier who has led Bahamas-based alternative investment and advisory firm Access Alternative Group S.A. for more than 20 years. According to the company, AAG and its affiliates have completed more than $5 billion in capital placements involving alternative fund managers, private and public startups, early-stage growth companies and targeted mergers and acquisitions across multiple sectors. Mr. Sawyer also serves on various corporate boards and advisory committees.

Lakshmi P. Kotra, PhD, President of Quantum BioPharma and CEO of Quantum BioPharma Australia Pty Ltd., is a Senior Scientist at the Krembil Brain Institute within University Health Network and Professor of Medicinal Chemistry at the University of Toronto. Dr. Kotra joined Quantum BioPharma in connection with the acquisition of Lucid Psycheceuticals in 2021 and is the recipient of the Julia Levy Award for contributions to the commercialization of biomedical innovation in Canada. His background includes research and development work involving anti-HIV drugs, antibacterials, insulin, antimalarials, medical cannabis therapeutics and treatments targeting multiple sclerosis.

Andrzej Chruscinski, MD, PhD, Vice-President, Clinical and Scientific Affairs, leads Quantum BioPharma’s clinical programs and clinical trial activities. Dr. Chruscinski received his MD and PhD from Stanford University, completed residency training in internal medicine at Stanford and fellowships in cardiology at Stanford and Toronto General Hospital. He has led major clinical trials involving transplantation tolerance and biomarker discovery and is a board-certified cardiologist.

Eric Hoskins, MD, DPhil, Director, is a physician and public health expert with more than 30 years of experience spanning healthcare, public policy, economic development and international trade. Dr. Hoskins previously served as Ontario’s Minister of Health and Long-Term Care and held several additional cabinet positions during nearly a decade as a member of provincial parliament. He also served as president of War Child Canada and was awarded the Order of Canada in 2007 for his humanitarian work.

For more information, visit the company’s website at www.QuantumBioPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM

• Earth Science Tech has positioned itself as a diversified healthcare holding company focused on pharmaceutical compounding, telemedicine, healthcare services, and strict capital allocation.
• The company recently completed a vertically integrated telehealth and pharmacy ecosystem through the launch of MyOnlineConsultation.com, with telemedicine capabilities supporting patient acquisition, while pharmacy operations drive high-margin recurring prescription-based revenue streams.
• Above all, Earth Science Tech emphasizes balance-sheet strength and capital discipline through ongoing share repurchase initiatives designed to reduce dilution and support shareholder value.
• The growing company operates multiple subsidiaries spanning compounding pharmacies, telehealth platforms, clinics, healthcare support services, real estate and cash management.

Over the past several years, Earth Science Tech (OTC: ETST), a strategic holding company, has undergone a significant transformation. Divesting legacy wellness operations, the company has repositioned itself to acquire and scale cash-flowing assets across healthcare, pharmaceutical compounding and telemedicine, alongside active cash management, through a growing network of subsidiaries operating under the umbrella of a diversified holding company structure.

Today, the company executes a strategy focused on acquiring and actively managing businesses capable of generating sustainable long-term cash flow across regulated healthcare, real estate, cash management, and related industries. That transition became more visible in March when Earth Science Tech announced the formal launch of MyOnlineConsultation.com through MOCTeledoc LLC, a telehealth division designed to provide integrated physician networks, technology infrastructure and clinical staffing services (https://ibn.fm/cAxV7).

The launch marked the completion of what management calls a vertically integrated healthcare ecosystem linking telemedicine consultations directly with the company’s pharmacy operations.

According to the company, MOCTeledoc completed its beta phase as a cash-flow-positive operation, an outcome management cited as validation of the division’s lean, high margin operating structure. The telehealth platform now connects directly with Earth Science Tech’s wholly owned compounding pharmacy subsidiaries, including RxCompoundStore.com and Mister Meds, while also maintaining flexibility to route prescriptions to external pharmacy partners when appropriate.

By internalizing the patient journey from front-end consultation to back-end prescription fulfillment, Earth Science Tech captures margin across the entire care continuum. In this model, telemedicine services often function as a low-friction customer acquisition channel for patients seeking consultations, customized medications or ongoing healthcare management. Compounding pharmacies, meanwhile, can generate high-retention, repeat prescription activity over extended periods. By linking the two operationally, Earth Science Tech optimizes customer lifetime value (“LTV”), creating a healthcare ecosystem where patient engagement, prescription fulfilment and clinical support reinforce one another internally.

The company’s healthcare operations are now spread across multiple subsidiaries.

RxCompoundStore.com, a licensed compounding pharmacy based in Florida, and Mister Meds based in Texas, are authorized to fulfil prescriptions across more than 33 U.S. states and Puerto Rico, with additional licensing expansion underway. Additional healthcare exposure comes through Peaks Curative, DOConsultations, and Las Villas Health Care, which together support telemedicine consultations, customized medication delivery, and specialized healthcare services including outreach to Spanish-speaking patient communities.

Outside healthcare, Earth Science Tech mitigates risk and builds tangible equity through Avenvi, its dedicated property development and cash management division. Avenvi serves as a vital pillar in the company’s broader strategy to generate non-correlated revenue streams and build hard asset value. The division manages its physical property developments and its real estate assets currently include multiple lots, one developed residential property, and the one standalone commercial property. Highlighting the operational synergies within Earth Science Tech’s holding structure, this commercial building serves as the physical operating facility for the company’s Mister Meds pharmacy subsidiary. By combining disciplined cash management with tangible real estate assets, Avenvi balances the high-growth nature of the healthcare subsidiaries with stable, alternative asset classes, anchoring the balance sheet and ensuring the holding company is not solely reliant on the medical sector, providing a durable foundation for long-term equity growth.

That diversified structure reflects the company’s broader holding company approach, leveraging assets and cash flows from multiple sectors. Importantly, management has also actively distinguished the company through rigorous capital allocation and shareholder-focused initiatives. 

One area that has drawn attention among investors is Earth Science Tech’s ongoing share repurchase activity. Unlike micro-cap peers reliant on dilutive financing, ETST utilizes free cash flow to systematically execute buybacks. This continuously reduces the number of publicly traded shares outstanding, directly mitigating dilution while signaling management confidence in long-term operating performance and fundamental value. The company has indicated that share retirement initiatives are expected to continue as part of its broader capital management strategy.

For micro-and small-cap public companies, disciplined capital allocation carries particular significance. Investors often scrutinize dilution risk closely, especially among emerging growth businesses operating in capital-intensive sectors. Earth Science Tech’s emphasis on stock buybacks, tangible asset growth through Avenvi, and self-funded scaling directly addresses those concerns while reinforcing strict balance-sheet discipline.

The company has also worked to strengthen its regulatory positioning, operating under SIC 2834 pharmaceutical classification standards and has securing FINRA Form 211 clearance, measures that improve transparency and market credibility among institutional and retail investors evaluating OTC-listed healthcare companies. 

The macroeconomic market backdrop supports ETST’s continued growth opportunities across expanding total addressable markets (“TAM”). The pharmaceutical compounding industry has expanded steadily as demand rises for personalized medications, dosage customization and flexible supply alternatives. Industry research cited by the company estimates the global compounding pharmacy market was valued at approximately US$13.1 billion in 2023 and could reach US$18.6 billion by 2030.

Telemedicine growth has been even more pronounced. Forecasts referenced by the company project the global telemedicine market could expand from approximately US$112 billion in 2025 to more than US$530 billion by 2034 as digital healthcare adoption accelerates. North America remains the largest regional telemedicine market.

Earth Science Tech’s integrated operating model to position the company at the intersection of diverse secular economic trends: scalable digital healthcare delivery, high-margin pharmaceutical fulfilment, and tangible asset accumulation through real estate and disciplined cash management. The company’s combination of recurring pharmacy revenue, telemedicine infrastructure, Avenvi’s active cash management and property holdings, and shareholder-focused capital management, distinguishes it from speculative, cash-burning early-stage healthcare companies operating in fragmented digital health markets.

For more information, visit the company’s website at www.EarthScienceTech.com.

NOTE TO INVESTORS: The latest news and updates relating to ETST are available in the company’s newsroom at https://ibn.fm/ETST

Disseminated on behalf of Powermax Minerals Inc. (CSE: PMAX) (OTCQB: PWMXF) and may include paid advertising.

• Powermax Minerals is expanding its North American rare earth element exploration portfolio across Canada and the United States to address the significant dependence on China for processed rare earth materials supporting key defense and industrial applications.
• China controls roughly 60% of global rare earth mining and approximately 90% of downstream processing capacity.
• Growing Pentagon demand for drones, missile systems, and advanced electronics, continues to ratchet up demand for secure non-Chinese rare earth supply chains.
• Powermax recently moved to acquire the Hopkins Rare Earths Project in northern Ontario, adding to projects in British Columbia, Ontario, and Wyoming.
  

As the United States accelerates efforts to rebuild domestic supply chains for critical minerals, exploration companies focused on rare earth elements are attracting growing investor attention. Among them is Powermax Minerals (CSE: PMAX) (OTCQB: PWMXF), a Canadian mineral exploration company focused on rare earth projects across North America. The company is assembling a portfolio of important rare earth element (“REE”) projects in North America at a time when geopolitical concerns and defense requirements are reshaping how governments approach strategic mineral supply.

Rare earth elements are essential to a broad range of modern technologies, including electric vehicles, wind turbines, advanced electronics, military guidance systems, jet engines, and permanent magnets. The growing demand must be met with increased mining as well as economical processing and refining.

Industry estimates indicate China controls approximately 60% of global rare earth mining and roughly 90% of downstream processing capacity. Beijing has also imposed export restrictions and licensing requirements on several heavy rare earth elements and related technologies, raising concerns in Washington and among allied governments about long-term supply security.

The issue has become particularly urgent for the U.S. defense sector. A recent report highlighted that the Pentagon has ordered tens of thousands of one-way attack drones, with plans to scale production beyond 300,000 units by early 2028. Each drone depends on rare earth magnets, while roughly 98% of global magnet manufacturing remains centered in China (https://ibn.fm/vi2bb).

According to the same report, more than 80,000 components across approximately 1,900 U.S. weapons systems rely on Chinese rare earth materials or components. These include drone motors, missile guidance systems, sensors and aerospace applications.

The distinction between light and heavy rare earth elements is becoming increasingly important in strategic planning. Light rare earths such as neodymium and praseodymium are commonly used in permanent magnets for electric vehicles and electronics. Heavy rare earths including dysprosium and terbium play a critical role in maintaining magnet performance under high temperatures and harsh operating conditions typical of military systems and aerospace applications.

Western governments are now attempting to reduce that dependency. The U.S. Department of Defense and other federal agencies have directed substantial funding toward rare earth development through government instruments including the Defense Production Act. The Pentagon’s investment activity has included equity participation and financing commitments designed to support domestic and allied supply chains.

At the same time, industry analysts caution that developing alternative processing capacity is a long-term undertaking. Building mines may take several years, but establishing metallurgical expertise, refining capability and qualified downstream manufacturing systems can require considerably longer.

That broader backdrop has helped increase interest in companies such as Powermax Minerals as a potentially critical component in the supply chain. The company’s portfolio includes the Cameron REE property in British Columbia, the Atikokan and Pinard projects in Ontario, and the Ogden Bear Lodge Project in Wyoming. 

Recently, Powermax also announced an option agreement to acquire a 100% interest in the Hopkins Rare Earths Project in northern Ontario. The Hopkins property covers approximately 5,900 hectares within the Clay-Howells Alkalic Rock Complex, a geological setting associated with rare earth exploration activity. Planned exploration work includes airborne geophysics, radiometric surveys, geological mapping and geochemical sampling. Management says the acquisition is intended to strengthen the company’s growing North American REE portfolio and increase exposure to jurisdictions viewed as geopolitically stable.

These developments come as global demand for rare earth elements is projected to rise sharply over the coming decade, driven by electrification, renewable energy deployment, artificial intelligence infrastructure, robotics and military modernization. Industry forecasts cited by the company suggest global REE demand could triple from approximately 59,000 tonnes in 2022 to roughly 176,000 tonnes by 2035.

For more information, visit the company’s website at www.PowermaxMinerals.com.

NOTE TO INVESTORS: The latest news and updates relating to PWMXF are available in the company’s newsroom at https://ibn.fm/PWMXF

Exploration Target Cautionary Statement

The exploration targets discussed are conceptual, and there is currently not enough data to confirm a mineral resource. Further exploration may not yield successful results.